Skip to main content

Table 1 Patients’ baseline data and clinical characteristics

From: Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment

Variable

Study sample

n = 56

N %

Gender

 females

50 89.3

 males

6 10.7

Age ± SD (range

43.3 ± 9.5 (21–60)

Previous lines of prophylactic medications

 Median value

3 (1–7)

Psychological comorbidities

 Anxiety

12 21.4

 Depression

12 21.4

 Anxiety and depression

10 17.9

 Bipolar disorder

3 5.4

 None

19 33.9